Evidence map›Paper›PMID 26380236›Full record

ArticleAdvanced biomedical research2015

Evaluation of the circulating CD34(+), CD309(+), and endothelial progenitor cells in patients with first attack of optic neuritis.

Masoud Etemadifar, Leila Dehghani, Hamid Ganji, Reza Soleimani, Maedeh Talebi, Nahid Eskandari, Fazel Sahraneshin Samani, Rokhsareh Meamar

Open access · goldAbstract read
In one paragraph

Article in Advanced biomedical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Masoud EtemadifarIsfahan Multiple Sclerosis and Neuroimmunology Research Center, Isfahan Eye Research Center, Ophthalmology Ward, Feiz Hospital, Isfahan, Iran.
Leila DehghaniIsfahan Neurosciences Research Center, AlZahra Hospital, Isfahan, Iran.
Hamid GanjiAlzahra Hospital Management, Isfahan University of Medical Sciences, Isfahan, Iran.
Reza SoleimaniDepartment of Biology, Payam Noor University, Isfahan, Iran.
Maedeh TalebiBiochemistry Labratory, Isfahan Al-Zahra Hospital, Isfahan, Iran.
Nahid EskandariDepartment of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Fazel Sahraneshin SamaniDepartment of Stem Cells, Royan Institute, Tehran, Iran.
Rokhsareh MeamarIsfahan Neurosciences Research Center, AlZahra Hospital, Isfahan, Iran.
Alzahra Medical and Education Center · IRIsfahan University of Medical Sciences · IRPayame Noor University · IRRoyan Institute · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndothelial progenitor cells (EPCs) are present in circulation and contribute to vasculogenesis in adults. The aim of the present study was to determine the number of circulating EPCs in patients with optic neuritis (ON). MATERIALS AND

methodsFifty patients with ON were diagnosed by expert neurologist and optometrist at the Feiz Hospital, Isfahan, Iran (2012-2013). Blood samples were collected from ON patients in the first attack. The number of EPCs was measured by flow cytometry through the assessment of CD34(+) and CD309(+) in patients and healthy individuals.

resultsWith using flow cytometry, CD34(+) and CD309(+) cells detected in peripheral blood cells of patients (n = 50) with ON, and healthy individuals (n = 30). Patients with ON had (mean = 66.71 ± 17.82) CD34(+) and CD309(+) cells compared with healthy controls (mean = 28.72 ± 22.46). In addition, there was no significant difference in CD309(+) cells in both groups.

conclusionThis study showed elevated CD34(+) and CD309(+) cells in the early stage of the disease. Regarded to EPC increment in neural repair, it expected the EPC level be increased in these patients, but no detectable differences were observed among both markers in healthy and patient with first attack.

Indexed as

CD309+CD34+endothelial progenitor cellsoptic neuritis

Identifiers

PMID26380236
PMCPMC4550950
OpenAlexW2153230020

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.